Compare DRTS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRTS | KIO |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Israel | United States |
| Employees | N/A | 2400 |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.1M | 478.7M |
| IPO Year | N/A | N/A |
| Metric | DRTS | KIO |
|---|---|---|
| Price | $7.64 | $11.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 319.3K | 136.5K |
| Earning Date | 11-20-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $10.52 |
| 52 Week High | $7.89 | $13.59 |
| Indicator | DRTS | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 78.12 | 49.22 |
| Support Level | $6.45 | $11.65 |
| Resistance Level | $5.14 | $11.73 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 92.04 | 55.00 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.